Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NH02D
- Development stage
- Unknown
- Lead developer
- NeuroHealing Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NH02D is a neurologically active small molecule drug developed by NeuroHealing Pharmaceuticals for the 'on-demand' treatment of premature ejaculation (PE). Administered orally, the drug is designed to delay ejaculation during sexual activity. NH02D was originally investigated in 2006 for the rehabilitation of patients with chronic motor and cognitive disabilities following a stroke, but the company subsequently repositioned the compound for specialty urological indications. While clinical testing in healthy volunteers has been reported, the specific active ingredient and its biological targets remain proprietary.
02
Targets
DRD (Dopamine receptors)ADRA1A (α1A)
Beyond the preview
Go deeper on NH02D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NH02D.